Table 4.

Percentage of participants engaging in specific intravaginal practices and laboratory parameters (vaginal flora, bacterial vaginosis, plasma, genital HIV RNA, IL-6, and IL-8) by condition. Plasma and CVL HIV RNA limit of detection was 20 copies/milliliter

	Experimental (SOC+ plus group intervention)			Enhanced standard of care (SOC+)			SOC+ versus experimental
	N(%) Median(IQR)			N(%) Median(IQR)
	Baseline (N = 58)	6-month (N = 47)	12-month (N = 54)	Baseline (N = 70)	6-month (N = 53)	12-month (N = 64)	6-month p-value	12-month p-value
Products used for intravaginal practices in the prior month
Water	90.9%	31.0%	40.7%	92.5%	45.8%	54.7%	0.159	0.140
Soap	63.6%	4.8%	27.8%	74.6%	29.2%	46.9%	0.013	0.042
Cloth, sponge or a rag	54.6%	2.4%	18.5%	52.2%	16.7%	37.5%	0.061	0.031
Traditional medicines	27.3%	2.4%	22.2%	29.9%	6.3%	42.2%	0.395	0.029
Herbs or flowers from outdoors	20.0%	2.4%	5.6%	16.4%	10.4%	14.1%	0.170	0.147
Lemon	10.9%	2.4%	9.3%	9.0%	2.1%	20.3%	0.924	0.111
Salt	7.3%	2.4%	5.6%	10.5%	2.1%	7.8%	0.924	0.629
Vinegar	3.6%	2.4%	7.4%	1.5%	2.1%	18.8%	0.924	0.090
Laboratory parameters
Abnormal vaginal flora	72.7%	61.0%	66.7%	82.1%	60.0%	50.9%	0.926	0.090
Bacterial vaginosis	60.0%	22.0%	27.5%	68.7%	11.1%	20.3%	0.186	0.383
Detectable plasma HIV RNA	18.2%	11.9%	11.1%	23.9%	18.8%	38.9%	0.379	0.086
Detectable CVL HIV RNA	12.7%	5.0%	5.6%	14.9%	15.9%	20.0%	0.134	0.244
IL-6 (n = 68; Exp = 35, SOC+ = 33)	306.3 (313.7)	326.0 (313.1)	--	282.6 (249.1)	330.1 (261.6)	--	0.762	--
IL-8 (n = 68; Exp = 35, SOC+ = 33)	380.11 (1311.9)	328.0 (1423.5)	--	227.5 (2285.5)	254.2 (1385.5)	--	0.651	--

SOC+ enhanced standard of care

CVL cervicovaginal lavage

Bold: p < 0.05